AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML

This article was originally published here

At the recommendation of an independent data monitoring committee (IDMC), and per the prespecified interim analysis plan, due to positive efficacy results at the first interim analysis for

The post AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply